The infant was admitted on 18 June 2025. Following extubation, oxygen saturation initially declined to 75–78% and recovered to 99% with mask ventilation. During a subsequent failed reintubation attempt, saturation fell again to 29% and improved after another period of mask ventilation. Spontaneous breathing resumed within 30 minutes. The clinical data were retrospectively analyzed, and the abstract reports that the multidisciplinary team applied airway-crisis management, stepwise oxygen therapy, glucocorticoid treatment, and family empowerment. A structured “warning-intervention-evaluation” closed-loop model was also implemented, with high-flow nasal cannula initiated within 30 minutes after extubation.

The case report identifies several observations from the episode. The recorded response time of the multidisciplinary team was less than one minute. The combination of corticosteroids, nebulization and high-flow nasal cannula was temporally associated with the avoidance of reintubation in this case, but the abstract does not establish that the intervention bundle caused that outcome. A structured seizure-monitoring protocol was temporally associated with recognition of neurological symptoms within 10 minutes of onset. Seizures were controlled, and computed tomography and electroencephalography results were reported as normal. The infant was discharged on day 8, and no events were reported at one-week follow-up.

Because this was a single case report based on retrospective clinical data, the findings describe the management of one former preterm infant and cannot establish effectiveness in a wider population. The authors state that the closed-loop model and early high-flow nasal cannula strategy may provide a reference pathway for perioperative care, while emphasizing that larger studies are required for validation. The abstract also identifies the absence of long-term neurodevelopmental follow-up as a limitation, so the report does not establish long-term neurological recovery. The published version is subject to further edits and is to be replaced automatically by the final Version of Record.

Subject of Research: Retrospective case report of multidisciplinary care for severe postoperative hypoxemia in a former preterm infant

Article Title: Multidisciplinary rescue and evidence-based nursing intervention for severe postoperative hypoxemia in a former preterm infant: a case report

Article References: Shao, Y., Hu, J., Zhang, G., Chen, M., & Xu, L. (2026). Multidisciplinary rescue and evidence-based nursing intervention for severe postoperative hypoxemia in a former preterm infant: a case report. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07682-w

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07682-w

Keywords: case report, postoperative hypoxemia, preterm infant, airway crisis, high-flow nasal cannula, multidisciplinary care, seizure monitoring, oxygen saturation, Multidisciplinary, rescue, evidence-based, nursing

The research team, led by investigators affiliated with Southern Illinois University School of Medicine, Wayne State University School of Medicine, and collaborating institutions, mined the TriNetX database, a federated network of de-identified electronic health records spanning the years 2006 to 2026. They identified adults with a stroke diagnosis who required invasive mechanical ventilation within 48 hours of stroke onset and who had documented pulse oximetry readings in that same early window. Patients were classified as receiving a restrictive oxygenation strategy if every recorded peripheral oxygen saturation, or SpO₂, value fell between 92 and 96 percent, and as receiving a liberal strategy if all values were at or above 97 percent. Anyone whose readings straddled both ranges or dipped below 92 percent was excluded, a deliberately strict rule designed to create two cleanly separated, non-overlapping exposure groups.

Of the 17,207 patients who met the inclusion criteria, 2,366 had restrictive oxygenation profiles and 14,841 had liberal profiles before any statistical adjustment. Because patients who end up on conservative oxygen protocols often differ systematically from those kept at higher saturations—older, sicker, with more cardiopulmonary disease—the researchers used propensity score matching, a statistical technique that pairs patients with similar baseline characteristics. The model accounted for age, sex, race and ethnicity, body mass index, a Glasgow Coma Scale score of nine or below, and a long list of comorbidities including hypertension, ischemic heart disease, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, pneumonia, and shock. After matching, 2,350 patients remained in each group, and all measured covariates were well balanced, with standardized mean differences below 0.1.

The results were striking. In the matched cohort, restrictive oxygenation during the first 48 hours of ventilation was associated with a 13 percent higher hazard of death at one month, with a hazard ratio of 1.13 and a 95 percent confidence interval of 1.03 to 1.23, a statistically significant finding with a p-value of 0.008. The association persisted at three months, with a hazard ratio of 1.11 and a confidence interval of 1.02 to 1.20. Kaplan–Meier survival curves, which track survival over time, visibly separated between the two groups in the combined stroke population, indicating that the mortality gap emerged early and persisted through the follow-up period.

When the investigators split the population by stroke subtype, the picture became more nuanced. In the acute ischemic stroke subgroup, built from 1,214 restrictive and 7,463 liberal patients before matching, restrictive oxygenation was associated with a 26 percent higher hazard of death at one month (hazard ratio 1.26, 95 percent confidence interval 1.11 to 1.43) and a 22 percent higher hazard at three months (hazard ratio 1.22, 95 percent confidence interval 1.08 to 1.37). In the intracerebral hemorrhage subgroup, however, the corresponding hazard ratios—1.09 at one month and 1.11 at three months—had confidence intervals that crossed one, meaning no statistically significant difference could be detected. The authors note that the hemorrhagic subgroup was smaller, with 728 patients per arm after matching, so limited statistical power may have masked a real effect; notably, the point estimates trended in the same direction as those seen in ischemic stroke.

The biology behind these findings is grounded in the peculiar physiology of the acutely injured brain. In the first two days after an ischemic stroke, cerebral autoregulation—the mechanism that normally keeps blood flow constant across swings in blood pressure—is often impaired. Surrounding the core of dead tissue lies the penumbra, a zone of hypoperfused but still viable brain that depends precariously on whatever oxygen the circulation delivers. Even modest reductions in arterial oxygen content could, in theory, tip penumbral tissue into irreversible infarction, extending the damage and worsening outcomes. A restrictive saturation target of 92 to 96 percent, while safe for many critically ill patients, may leave less reserve for this vulnerable tissue than a liberal target of 97 percent or above.

Yet the push toward conservative oxygen in intensive care has its own logic. Excess oxygen generates reactive oxygen species, drives oxidative stress, and can cause cerebral vasoconstriction, and randomized trials in general ICU populations—including ICU-ROX and the Oxygen-ICU trial—have explored whether tighter oxygen control reduces harm. The new study suggests that extrapolating those protocols to stroke patients may be misguided. The authors point to post-hoc analyses of ICU-ROX as a telling parallel: among ventilated patients with acute brain pathologies other than hypoxic-ischemic encephalopathy, 180-day mortality was numerically higher under conservative oxygen (34.5 percent versus 26.9 percent), a heterogeneity considered plausible enough to be formalized as a prespecified hypothesis in the ongoing Mega-ROX Brains trial, which is randomizing brain-injured patients to conservative or liberal oxygenation targets.

Among the secondary outcomes, one result stood out as counterintuitive: patients in the restrictive group were significantly less likely to undergo tracheostomy within 30 days, at 8.5 percent versus 13.1 percent in the liberal group, a risk ratio of 0.653 with a p-value below 0.001. The authors caution that this pattern may reflect survivorship bias—patients who die early cannot receive a tracheostomy—or may be shaped by unmeasured factors such as the reasons for intubation, the trajectory of neurological recovery, and goals-of-care discussions that could not be captured in the database. Ventilator-associated pneumonia, by contrast, showed no significant difference between groups, with event rates of 0.6 percent and 0.89 percent, though the very low number of events limited statistical power.

The study’s observational design imposes important caveats. Because oxygenation was observed rather than allocated, residual confounding by unmeasured variables cannot be excluded, and the association cannot be read as proof of causation. Stroke severity measures such as infarct volume, hematoma size, and detailed neurological examinations were not available in the federated record network and could not be incorporated into the matching model. The exposure was defined by documented pulse oximetry readings rather than continuous arterial oxygen measurements, so the analysis reflects oxygenation strategy rather than precise quantification of hyperoxemia or hypoxemia. The two saturation thresholds are also adjacent, making the contrast between groups relatively narrow, and follow-up was limited to three months.

Even with those limitations, the sheer size of the cohort and the rigor of the matching make this one of the most pointed challenges yet to the assumption that conservative oxygen targets are universally safe. The authors frame their findings as hypothesis-generating rather than practice-changing, but the implication is hard to ignore: the first 48 hours of mechanical ventilation may represent a modifiable window in stroke care, and the optimal saturation target may differ between an ischemic brain starved of blood flow and a hemorrhagic brain compressed by expanding blood. As stroke remains a leading cause of death and disability worldwide, the authors argue that disease-specific randomized trials—rather than broad ICU-wide oxygen protocols—are urgently needed to determine whether liberal oxygenation genuinely protects the penumbra, or whether individualized titration can balance the competing risks of hypoxemia and oxygen toxicity in this uniquely vulnerable population.

Subject of Research: Oxygen saturation targets and short-term mortality in mechanically ventilated stroke patients

Article Title: Association of liberal versus restrictive oxygen saturation targets with mortality in mechanically ventilated stroke patients: a multicenter retrospective propensity-matched analysis

Article References: Ghafarian, A., Saad, J., Wajahath, M., Ghafarian, M., Saasouh, W., Saleh, K., Nasser, M., Badami, A., Shahait, A. D., & Loggini, A. (2026). Association of liberal versus restrictive oxygen saturation targets with mortality in mechanically ventilated stroke patients: a multicenter retrospective propensity-matched analysis. Frontiers in Neurology, 17, 1840183. https://doi.org/10.3389/fneur.2026.1840183

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1840183

Keywords: stroke, mechanical ventilation, oxygen saturation, acute ischemic stroke, intracerebral hemorrhage, mortality, propensity score matching, critical care, neurocritical care, TriNetX, hyperoxia, ventilator-associated pneumonia

The study, led by Liz E. Lezama Oropeza, with colleagues Elisa Basora-Rovira and Aarti Shakkottai, reviewed polysomnographic data from fifteen infants between zero and twelve months of age who were born at term and had no identified syndromes. The mean gestational age of the cohort was 38.4 weeks, with a narrow spread of plus or minus 0.6 weeks, and eighty percent of the infants were male. The average age at the first sleep study was 7.5 months, with a standard deviation of 3.6 months, meaning the group spanned early infancy through the first birthday.

Polysomnography, the gold-standard overnight sleep test, records brain waves, breathing effort, airflow, oxygen saturation, carbon dioxide levels, and body movements to quantify how often breathing is disrupted during sleep. In this cohort, the average apnea-hypopnea index, or AHI, which counts the number of apneas and hypopneas per hour of sleep, was 23.1 events per hour. The mean obstructive AHI, which isolates events caused by physical blockage of the upper airway, was 20 events per hour, while the mean central apnea index, reflecting pauses in breathing driven by immature or irregular brainstem signaling rather than airway obstruction, was 3.1 events per hour. For context, an obstructive AHI above 5 events per hour is generally considered moderate sleep apnea in pediatric populations, so the average infant in this series fell well into the moderate-to-severe range.

Oxygenation data added another layer of concern. Mean oxygen saturation during sleep was 97.5 percent, but the mean nadir, the lowest saturation reached during any single desaturation event, was 81.0 percent, with a wide standard deviation of 9.9 percent. Six of the fifteen infants met formal criteria for sleep-related hypoxemia, defined in this study as oxygen saturation below 90 percent for at least five minutes during the recording. Carbon dioxide measurements told a different story: mean and peak carbon dioxide levels were 35 and 48.6 millimeters of mercury, respectively, and none of the patients met criteria for sleep-related hypoventilation, which would require elevated carbon dioxide above 50 millimeters of mercury for more than a quarter of total sleep time. The pattern suggests that in these otherwise healthy infants, the dominant problem was intermittent airway obstruction causing repeated oxygen dips rather than sustained underventilation.

The clinical picture preceding referral was often subtle. Only a third of the infants had documented snoring, the symptom most parents and clinicians associate with sleep apnea, and nearly half, forty-seven percent, carried a diagnosis of gastroesophageal reflux, a condition that has been linked to airway inflammation and laryngeal hypersensitivity in infants. Seventy-three percent of the infants underwent some form of upper airway evaluation, such as flexible laryngoscopy, and seven of those evaluations revealed abnormal findings. Laryngomalacia, a condition in which immature, floppy supraglottic tissue collapses inward during inspiration, is the most common congenital cause of stridor and obstructive events in infants and featured among the abnormal findings in this series.

Follow-up polysomnography, obtained in ten of the fifteen infants at an average age of around 13.4 months, provided the study’s most striking finding. Four of the ten infants showed complete resolution of their sleep-disordered breathing without any surgical or device-based intervention. One infant achieved resolution while using continuous positive airway pressure, or CPAP, a machine that delivers a steady stream of pressurized air through a mask to splint the airway open during sleep, but was subsequently lost to follow-up. In the remaining five infants, sleep-disordered breathing persisted but improved. The researchers also examined whether disease severity tracked with age, finding a weak negative correlation between AHI and age, with a Spearman rho of minus 0.31 and a p-value of 0.26, which did not reach statistical significance in this small sample but pointed in the direction of decreasing severity as infants matured.

The authors emphasize that the frequency of moderate-to-severe obstructive sleep apnea in this population is high, but that the clinical implications remain unclear. Diagnostic thresholds for sleep-disordered breathing in infants are poorly standardized, and much of the pediatric literature derives normative values from older children or from high-risk infant populations whose airway physiology differs substantially. The infant upper airway is anatomically distinct: narrow cartilaginous structures, predominantly nasal breathing, high airway compliance, and immature neuromuscular control of the pharyngeal dilator muscles all predispose to collapse during sleep, particularly during active or rapid eye movement sleep when muscle tone falls. As infants grow, the airway enlarges, adenoid and tonsillar tissue relative to the airway changes, and neuromuscular control matures, which may explain why many infants in this series appeared to outgrow their disease.

The study has clear limitations that the authors acknowledge. As a single-center case series of fifteen infants, it cannot establish prevalence in the broader population of healthy term infants, since all participants were referred for suspected sleep-disordered breathing at a tertiary care center. The weak correlation between age and AHI did not reach statistical significance, and the follow-up cohort was small, with five of fifteen infants lacking repeat sleep studies. The authors also note that there is limited data on effective treatment strategies for this group, and that the natural history of untreated moderate-to-severe disease in otherwise healthy infants remains poorly characterized.

Nevertheless, the findings carry practical weight for parents and clinicians. Snoring in a full-term baby without a syndrome is not a reliable screening sign, appearing in only a third of this cohort, and reflux may be a more common companion diagnosis than previously appreciated. The authors conclude that further research is warranted to refine diagnostic thresholds and standardize the diagnostic evaluation and interventions for sleep-disordered breathing in this unique population. Until larger, prospective studies establish normative infant polysomnography values and clarify which infants need intervention versus watchful waiting, the study suggests that clinicians evaluating otherwise healthy infants for suspected sleep-disordered breathing should maintain a low threshold for overnight testing, while recognizing that a substantial share of these babies may simply grow out of it.

Subject of Research: A case series of fifteen term, non-syndromic infants referred for suspected sleep-disordered breathing found high rates of moderate-to-severe obstructive sleep apnea on polysomnography, with many infants outgrowing the condition by follow-up.

Article Title: Correlation between phenotype and polysomnography findings of sleep-disordered breathing in term, non-syndromic infants: a case series study

Article References: Lezama, L., Basora-Rovira, E., & Shakkottai, A. (2026). Correlation between phenotype and polysomnography findings of sleep-disordered breathing in term, non-syndromic infants: a case series study. Frontiers in Sleep, 5, Article 1877709. https://doi.org/10.3389/frsle.2026.1877709

Image Credits: AI Generated

DOI: 10.3389/frsle.2026.1877709

Keywords: infant sleep apnea, sleep-disordered breathing, polysomnography, apnea-hypopnea index, laryngomalacia, gastroesophageal reflux, oxygen saturation, hypoxemia, CPAP, term infants, Frontiers in Sleep, pediatric sleep

The choice of the specific parameters measured in this study reflects both practical constraints and the priorities of space medicine. Body weight, core body temperature, blood pressure, heart rate, and peripheral oxygen saturation are inexpensive, quick, and reliable to obtain in a confined habitat without specialized equipment, making them feasible for repeated measurement by crew members themselves. Each parameter also serves as a proxy for a distinct physiological system. Body weight integrates fluid balance, energy intake, and expenditure, and shifts in weight during confinement can signal changes in dietary habits, hydration, or activity levels. Blood pressure and heart rate reflect cardiovascular regulation and, indirectly, autonomic nervous system tone, which is sensitive to stress, sleep quality, and physical activity. Core body temperature relates to thermoregulation and circadian rhythmicity, both of which can be disrupted when natural light cycles and environmental variability are removed. Peripheral oxygen saturation, while generally stable in healthy individuals at sea level, provides a safety margin check that can detect respiratory or environmental problems. Together, these five measures form a minimal but informative panel for monitoring crew health in resource-limited settings.

The pronounced inter-individual variability observed, particularly for body weight and cardiovascular measures, deserves careful attention because it mirrors one of the most consistent findings across analog and spaceflight literature. Individual responses to identical environmental stressors can diverge substantially, influenced by baseline fitness, habitual diet, sleep chronotype, stress coping styles, and prior experience with confined or expeditionary settings. In the Mars500 experiment, for example, crew members showed markedly different patterns of sleep-wake disruption and activity over the 520-day simulated mission, and similar heterogeneity has been documented in Antarctic overwintering personnel. This variability has practical consequences: group-level averages can mask clinically meaningful changes in individual crew members, which argues for personalized monitoring approaches in which each individual serves as their own control. It also complicates the design of analog studies, since small cohorts drawn from a variable population may not represent the range of responses expected in larger, more diverse astronaut corps.

The methodological decision to rely on descriptive statistics rather than inferential testing reflects a common and often underappreciated challenge in analog research. With 40 participants measured at three time points, the dataset is respectable by the standards of analog missions, which frequently involve crews of four to six individuals. Even so, the authors found that several variables deviated from normal distributions, as assessed with Q-Q plots, which undermines the assumptions underlying parametric tests such as repeated-measures analysis of variance. Non-normal distributions of physiological parameters in small samples can arise from genuine biological heterogeneity, from measurement variability, or from the bounded nature of some measures such as oxygen saturation, which clusters near its physiological ceiling. When distributional assumptions fail, inferential tests lose their interpretability, and presenting medians, ranges, and distribution shapes becomes more honest than reporting p-values that may be unstable or misleading. This approach also guards against overinterpreting random fluctuation as meaningful adaptation, a pitfall that has affected some smaller analog studies.

The measurement schedule itself, with assessments on Days 1, 7, and 14, represents a compromise between scientific resolution and operational feasibility. Weekly sampling can capture broad trends and identify whether parameters drift over the mission, but it cannot resolve day-to-day fluctuations that may carry their own information. Heart rate and blood pressure, for instance, are influenced by acute factors such as sleep quality, caffeine intake, exercise timing, and even the stress of being measured, and single daily readings may not distinguish between transient variation and genuine directional change. The authors’ call for higher-frequency monitoring in future studies aligns with a broader trend in space health research toward continuous or near-continuous ambulatory monitoring using wearable sensors. Such devices can capture heart rate variability, activity levels, and sleep patterns around the clock, providing a far richer picture of autonomic adaptation than episodic spot checks. However, wearables introduce their own challenges in confined habitats, including sensor drift, skin irritation, data management, and the psychological effect of constant observation on crew behavior.

The LunAres Research Station itself is worth situating within the broader landscape of analog facilities. Located in Piła, Poland, it operates as an isolated habitat in which crews live and work without access to the external environment for the duration of a mission, simulating key characteristics of what researchers term ICE environments: isolated, confined, and extreme. Unlike facilities that simulate specific planetary surfaces, such as HI-SEAS on Hawaiian volcanic terrain or stations designed around Martian regolith scenarios, LunAres emphasizes the human factors dimension of isolation, with modular living quarters, laboratory space, a gym, and a kitchen arranged around a central research area. This design makes it particularly suitable for studies of behavioral health, crew dynamics, and physiological monitoring under confinement, complementing facilities whose primary value lies in geological or operational realism. The diversity of analog platforms is itself an asset, since different facilities isolate different subsets of the stressors experienced in spaceflight, allowing researchers to attribute effects more precisely.

It is important to recognize what this study deliberately does not model. Microgravity, space radiation, and the specific hazards of launch and landing are absent by definition in a terrestrial habitat, and the authors are explicit that their aim was not to replicate spaceflight physiology. This transparency matters because analog findings are sometimes overextended in popular reporting, with confinement effects conflated with the cardiovascular deconditioning or bone loss caused by weightlessness. What analogs like LunAres isolate is the psychological and behavioral component of spaceflight: the loss of environmental variety, the enforced proximity to a small group, the structured routines, and the separation from family and normal social life. These stressors are genuinely relevant to long-duration missions, and their physiological correlates, such as altered sleep, changed activity patterns, and stress-mediated cardiovascular adjustments, can be studied without the enormous cost and rarity of orbital research. The finding that short-term confinement alone did not perturb basic physiological parameters suggests that, for healthy adults, the psychological stress of a two-week isolation is within the adaptive capacity of normal homeostatic mechanisms.

The emphasis on standardized measurement protocols in the authors’ conclusions points to a persistent weakness in the analog literature. Because analog studies are conducted by many independent groups with different instruments, timing conventions, and definitions of baseline, results are difficult to compare or pool. Blood pressure measured after rest versus after activity, body temperature measured orally versus tympanically, and weight measured at different times of day relative to meals can all yield systematically different values. Establishing community standards for measurement timing, posture, instrumentation, and data reporting would allow individual studies to contribute to a cumulative evidence base rather than existing as isolated snapshots. The authors’ observation that routine parameters are often interpreted without adequate consideration of confounders such as hydration status, circadian phase, and recent physical activity is a pointed reminder that even simple measurements require careful protocol design to be interpretable.

The prospective observational design, in which measurements were planned before the mission and collected at fixed time points, strengthens the study relative to retrospective analyses of mission records, though it remains observational in the strict sense. Without a control group experiencing the same schedule outside confinement, the study cannot attribute any observed change specifically to isolation, and indeed the absence of temporal trends means there is little to attribute. This limitation is inherent to analog research, where the practical and ethical difficulty of isolating a matched control group for two weeks is considerable. Some studies address this by comparing mission data with pre-mission baseline periods or with crew members’ habitual routines, and future LunAres studies could incorporate such baseline extensions to sharpen inference.

Finally, the study’s framing of physiological stability as a finding in its own right, rather than as a failure to detect effects, is a useful corrective to publication norms that favor dramatic results. Demonstrating that a well-controlled two-week confinement does not destabilize basic cardiovascular, thermal, and metabolic markers in healthy adults provides a reassuring data point for short-duration mission planning and establishes a baseline against which longer missions can be compared. The authors’ recommendation to add psychological markers alongside physiological ones acknowledges that the most consequential effects of isolation may be behavioral rather than vital-sign-based, and that integrated monitoring of mood, cognition, sleep, and interpersonal dynamics will be essential as mission durations extend toward the months and years required for lunar surface operations and eventual journeys to Mars.

Subject of Research: Physiological monitoring of healthy adults during a 14-day isolated analog space mission

Article Title: Analytical comparison of physiological parameters in participants during an analog space mission

Article References: Kijak, K., Lubkowska, A., Skomro, P., Ardan, R., Budkowska, M., Gronwald, B., Gronwald, H., Stachowska, E., Kijak, K., Orzechowski, L., Mintus, A., & Lietz-Kijak, D. (2026). Analytical comparison of physiological parameters in participants during an analog space mission. Frontiers in Space Technologies, 7, Article 1752453. https://doi.org/10.3389/frspt.2026.1752453

Image Credits: AI Generated

DOI: 10.3389/frspt.2026.1752453

Keywords: space analog mission, isolation, LunAres Research Station, physiology, blood pressure, heart rate, body temperature, oxygen saturation, space medicine, confinement, inter-individual variability, Analytical

The research, conducted at HOCH Health Ostschweiz in St. Gallen and published in Frontiers in Neuroimaging, revisited a retrospective series of seven consecutive patients diagnosed with AZOOR between 2005 and 2025. The team, led by Scott Tschuppert, Christophe Valmaggia, and Margarita G. Todorova, combined the full arsenal of modern retinal diagnostics—optical coherence tomography, fundus autofluorescence, near-infrared reflectance, fluorescein angiography, visual field testing, and two forms of electroretinography—with a technique called retinal oximetry. The goal was ambitious: to see whether AZOOR leaves a measurable metabolic fingerprint that could distinguish it from retinitis pigmentosa, a hereditary disease it can superficially mimic.

The cohort itself reflects the typical face of AZOOR. Five of the seven patients were women, with a median age of just 28 years and a range spanning 20 to 53. Six patients had symptoms in only one eye at presentation. Their complaints ranged from scotomas and photopsias to reduced visual acuity and color desaturation. Diagnostic delay varied widely, from as little as eight days to as long as 180 days, underscoring how easily this condition slips past initial examination. One patient had a preceding flu-like illness, another later developed thoracic herpes zoster, and one had bilateral congenital aniridia, with AZOOR assigned clinically to a single presenting eye.

On structural imaging, the disease left its mark consistently. Spectral-domain optical coherence tomography revealed disruption or irregularity of the ellipsoid zone—the thin band corresponding to the inner segments of photoreceptors—in every affected eye. Fundus autofluorescence showed patchy hyperautofluorescence, and near-infrared reflectance imaging displayed the trizonal patterns that have become a hallmark of the disorder. Multifocal electroretinography, which maps macular function point by point, detected macular dysfunction in six of seven patients. Full-field electroretinography, by contrast, was abnormal in only five patients and entirely normal in others, confirming that AZOOR is fundamentally a focal, zonal process rather than a uniform degeneration.

The real novelty lay in the oximetry data. The technique relies on a simple physical principle: oxygenated and deoxygenated hemoglobin absorb light differently at different wavelengths. The Oxymap T1 oximeter mounted on a fundus camera captures images simultaneously at 586 nanometers, where absorption is insensitive to oxygen, and at 605 nanometers, where it is oxygen-sensitive. Software then calculates the optical density ratio for each vessel segment, yielding an estimate of hemoglobin oxygen saturation. Measurements were taken in a predefined peripapillary zone, between concentric circles of two and three optic-disc diameters centered on the optic nerve. Complete arterial and venous data were available for eight eye-level measurements from four AZOOR patients, which were compared against an existing institutional dataset of 22 eyes from 15 healthy controls and 42 eyes from 21 retinitis pigmentosa patients.

The numbers told a striking story. Across the AZOOR measurements, mean arteriolar oxygen saturation was 95.2 percent, noticeably below the 99.1 percent seen in healthy controls and the 101.3 percent recorded in the retinitis pigmentosa group. Meanwhile, venular saturation was unremarkable at 67.3 percent, and consequently the arteriovenous difference—a surrogate for how much oxygen the retina actually consumes—was compressed to 27.9 percent, versus roughly 34 to 36 percent in the other groups. Kruskal–Wallis testing across all three groups confirmed significant intergroup differences for arteriolar saturation and the arteriovenous difference, while exploratory pairwise Mann–Whitney comparisons showed that AZOOR was significantly lower than both controls and retinitis pigmentosa on both parameters. Venous saturation, intriguingly, did not differ among the groups at all.

Why does this matter? The comparison with retinitis pigmentosa is the intellectually satisfying part. In that degenerative disease, photoreceptors—especially oxygen-hungry rods—die off progressively. When the tissue’s metabolic demand collapses, less oxygen is extracted from the blood, so vessels carry away oxygen they never delivered, and measured saturation rises. Some retinitis pigmentosa values even exceed 100 percent, a recognized calibration artifact of altered vessel caliber and changed retinal optics rather than true supersaturation. AZOOR shows the opposite pattern: lower arterial saturation despite outer retinal damage. Reduced oxygen consumption alone cannot explain this, because dying photoreceptors should push saturation up, not down. Something else is going on—possibly vascular dysregulation, inflammation-associated vascular change, or disease-related optical effects, though the authors are careful to label all such explanations hypothetical.

This metabolic profile is biologically plausible in the context of an inflammatory disease. In uveitic conditions such as Vogt-Koyanagi-Harada disease and Behçet disease, retinal oxygen metabolism and vascular parameters shift measurably, and occlusive vasculitis can be documented with angiography and optical coherence tomography angiography. The AZOOR pattern is compatible with localized inflammatory or vascular dysregulation—though oximetry measures saturation, not blood flow, so it cannot by itself prove occlusion or reduced perfusion. The researchers emphasize that because oximetry was performed at wildly different disease stages, roughly 15 days after symptom onset in one patient and up to 120 months in another, these findings represent a disease-associated pattern observed during routine follow-up, not evidence of acute inflammatory activity.

The caveats deserve honest acknowledgment. AZOOR is rare, and seven patients is a small sample by any standard; oximetry was available in only four of them because the instrument arrived at the clinic after several patients had completed care. Both eyes of the same individual were analyzed when available, violating statistical independence, and the exploratory comparisons were not corrected for multiple testing. The retinitis pigmentosa and control data came from a separate institutional dataset without a standardized severity classification. The authors themselves frame the p-values as hypothesis-generating rather than confirmatory. A sensitivity analysis excluding the patient with congenital aniridia left the direction of all findings unchanged, which strengthens the signal somewhat, but nobody is claiming a diagnostic threshold yet.

Still, the conceptual advance is real. By adding a metabolic vascular parameter to a phenotyping workflow traditionally built on structure and electrophysiology, the St. Gallen team has sketched what a complete multimodal assessment of AZOOR could look like: arterial, venous, and arteriovenous oxygen metrics layered onto OCT segmentation, wide-field autofluorescence mapping, OCT angiography, adaptive optics imaging, and longitudinal visual field and ERG outcomes. If prospective studies confirm that AZOOR’s low arterial saturation and reduced oxygen extraction persist or evolve in a characteristic way, retinal oximetry could become a practical biomarker for monitoring disease activity and, eventually, for testing treatments in a condition where no controlled therapeutic trial has ever been completed. For a disease discovered more than thirty years ago and still lacking a known cause, a new window on its metabolism is a genuinely exciting development.

Subject of Research: Retinal oxygen saturation measured with oximetry in acute zonal occult outer retinopathy compared with retinitis pigmentosa and healthy controls

Article Title: Distinct retinal oxygenation patterns in acute zonal occult outer retinopathy assessed by multimodal imaging

Article References: Tschuppert, S., Valmaggia, C., & Todorova, M. G. (2026). Distinct retinal oxygenation patterns in acute zonal occult outer retinopathy assessed by multimodal imaging. Frontiers in Neuroimaging, 5, Article 1902215. https://doi.org/10.3389/fnimg.2026.1902215

Image Credits: AI Generated

DOI: 10.3389/fnimg.2026.1902215

Keywords: AZOOR, retinal oximetry, retinitis pigmentosa, oxygen saturation, multimodal imaging, ellipsoid zone, electroretinography, optical coherence tomography, outer retinopathy, retinal metabolism, ophthalmic imaging, autofluorescence

The stakes are high. PPHN affects roughly two to six infants per 1,000 live births worldwide and accounts for about 10 percent of neonatal intensive care deaths. In developing countries, reported mortality climbs to as high as 20 percent, a gap driven largely by inequities in access to the gold-standard therapies. Inhaled nitric oxide, which directly relaxes pulmonary vessels, and extracorporeal membrane oxygenation, which oxygenates blood outside the body, both require expensive infrastructure and specialist teams that many hospitals in low- and middle-income countries simply cannot provide. Even where nitric oxide is available, abruptly stopping it can trigger a dangerous rebound spike in lung pressures, and prolonged mechanical ventilation risks chronic lung injury.

Into this therapeutic vacuum steps sildenafil, a selective inhibitor of the enzyme phosphodiesterase type 5. By blocking the breakdown of cyclic guanosine monophosphate, or cGMP, sildenafil amplifies the nitric oxide signaling pathway that tells pulmonary arteries to dilate. The drug is cheap, stable, and can be given by mouth, making it an attractive option where inhaled therapies are out of reach. Previous trials and observational series, including work from Baquero and colleagues and more recent studies, have suggested that sildenafil can improve oxygenation in neonates with an acceptable safety profile, but the response varies with disease severity, underlying causes, and comorbidities such as sepsis or heart muscle dysfunction.

The Surabaya team mined electronic medical records for all neonates diagnosed with PPHN who received oral sildenafil between January 2024 and October 2025. To enter the paired before-and-after analysis, babies needed complete documented measurements of heart rate, respiratory rate, and peripheral oxygen saturation both before the first sildenafil dose and at the final assessment before the drug was stopped or the baby was discharged. Those who died, were transferred, or lacked complete records were excluded, a point that would later prove crucial for interpreting the results. The final cohort comprised 54 neonates, and because no commercial neonatal formulation of sildenafil exists, hospital staff crushed 20-milligram adult tablets and dispersed them in water immediately before each oral dose.

The demographic picture was strikingly consistent with known PPHN epidemiology. Every baby in the cohort began treatment within the first week of life, all within days zero to seven. Males outnumbered females 57.4 percent to 42.6 percent, and 87 percent were term infants, echoing the well-established pattern that PPHN preferentially strikes term or near-term babies whose circulations must make the dramatic transition from fetal to neonatal physiology. Nearly all weighed at least 2,500 grams at birth, and 98 percent never needed invasive mechanical ventilation, though a small number received continuous positive airway pressure. Comorbidity, however, was the rule rather than the exception, with metabolic or systemic disorders present in 74 percent, pulmonary diseases such as respiratory distress syndrome and meconium aspiration in 43 percent, sepsis in 26 percent, congenital heart defects in 20 percent, and birth asphyxia in nearly 15 percent.

The dosing patterns reveal the pragmatic reality of neonatal pharmacology in a tertiary Indonesian hospital. Nearly two-thirds of the infants, 63 percent, received doses above 0.5 milligrams per kilogram per dose, while the rest received less. The overwhelming majority, 96.3 percent, were dosed four times daily, reflecting the drug’s pharmacokinetic profile and the prevailing practice in neonatal PPHN. Treatment was typically brief: 70 percent of babies received sildenafil for a week or less, 28 percent for one to two weeks, and only a single infant for 15 days or more. The average duration was 6.4 days, with a range of 3 to 36 days, suggesting that most babies either stabilized quickly or had their therapy escalated or redirected. Dose selection and adjustment rested entirely on the clinical judgment of the attending neonatologists, since no standardized protocol governed the practice.

The headline clinical finding concerned breathing. The mean respiratory rate fell from 53.44 breaths per minute before treatment to 49.63 breaths per minute at the final documented assessment, a statistically significant decrease confirmed by the Wilcoxon signed-rank test with a p-value of 0.008. Heart rate, by contrast, remained essentially unchanged, edging from 137.28 to 136.87 beats per minute with no statistical significance, a stability that is pharmacologically reassuring in principle, since a falling heart rate in a critically ill neonate can signal either recovery or cardiovascular deterioration. Peripheral oxygen saturation rose numerically from 96.37 to 97.26 percent, but the change fell just short of significance at p equals 0.067, likely because many babies started near the ceiling of what pulse oximetry can register, a classic ceiling effect compounded by concurrent oxygen supplementation.

The authors are admirably candid about what these numbers cannot prove. Because every baby also received routine supportive care, most notably oxygen therapy, and because there was no comparator group receiving placebo or standard treatment alone, the observed improvements represent the combined effect of everything done in the unit, not the isolated action of sildenafil. The complete-case design compounds the problem: babies who died or were transferred had to be excluded from the paired analysis, and those infants were likely the sickest, meaning the favorable changes may be overestimated. Detailed information on oxygen delivery methods, concentrations, and timing was inconsistently recorded, so even the contribution of supportive therapy cannot be disentangled from the drug’s effect. The safety picture is similarly incomplete, as blood pressure changes and adverse events were not assessed under a standardized prospective monitoring protocol.

What the study does deliver is a rare, granular portrait of how sildenafil is actually prescribed in a real-world, resource-constrained environment, filling a gap left by most evidence, which comes from high-income countries and tightly controlled settings. It documents that Indonesian neonatologists are reaching for the higher end of the per-dose dosing range, favoring four-times-daily regimens, and generally achieving short treatment courses. It also confirms the expected epidemiology of PPHN in a tertiary referral population, with its heavy burden of comorbid disease shaping each baby’s trajectory. The pharmacological rationale remains sound: preserving cGMP should lower pulmonary vascular resistance and ease the work of breathing, and the significant respiratory rate reduction is consistent with that mechanism, even if causation cannot be claimed.

The research team concludes that prospective, controlled trials are now essential, ideally incorporating standardized sildenafil dosing protocols, comprehensive hemodynamic monitoring including blood pressure, and serial echocardiographic assessment of pulmonary pressures. Until such studies are done, oral sildenafil will continue to serve as an accessible lifeline in settings where inhaled nitric oxide is a luxury, and clinicians will weigh its growing but incomplete evidence base against the urgent needs of newborns whose lungs will not yet accept the air around them. For the 54 babies whose records told this story, the trajectory was, on balance, one of improvement, a cautiously hopeful signal from a drug that costs pennies but targets one of neonatal medicine’s most lethal failures of transition.

Subject of Research: Oral sildenafil use and clinical outcomes in neonates with persistent pulmonary hypertension of the newborn

Article Title: Utilization pattern of oral sildenafil and changes in clinical parameters among neonates with persistent pulmonary hypertension: A retrospective study in an Indonesian hospital

Article References: Yulistiani, Rohmaan, Y., Utomo, F. N., Nurhariansyah, R., Nusantara Ratri, D. M., Nilamsari, W. P., & Dewi, D. M. R. D. (2026). Utilization pattern of oral sildenafil and changes in clinical parameters among neonates with persistent pulmonary hypertension: A retrospective study in an Indonesian hospital. Pharmacia, 73, Article e205304. https://doi.org/10.3897/pharmacia.73.e205304

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e205304

Keywords: persistent pulmonary hypertension of the newborn, sildenafil, neonatology, pulmonary vasodilator, oxygen saturation, retrospective study, Indonesia, neonatal intensive care, phosphodiesterase type 5 inhibitor, resource-limited settings, heart rate, respiratory rate

The study, led by researchers including Edgar Cristancho-Mejía and Walter Schmidt, recruited healthy, non-smoking adults who had lived at their respective altitudes for at least two years. Participants came from six locations spanning 970 to 2600 meters, including regions around Bogotá in the Central Eastern Andes and the lower Western Andes near Tuluá and Cali. Crucially, none of the participants were endurance athletes, eliminating a major confounding factor that has plagued earlier comparisons between highland populations and sea-level dwellers. The cohort included 133 men and 148 women, with ancestry distributions reflecting the regional population mix of African, European, and Native American heritage.

Measuring hemoglobin mass directly is technically demanding, and the team used the optimized carbon monoxide rebreathing method, widely regarded as the gold standard. Participants inhaled a precisely calculated dose of carbon monoxide over two minutes, and the researchers tracked how much of it bound to hemoglobin in the blood, allowing an accurate calculation of total hemoglobin mass. From this, together with venous hemoglobin concentration and hematocrit, the team derived red cell volume, plasma volume, and total blood volume. Blood samples drawn from a cubital vein provided hemoglobin concentration, hematocrit, and oxygen saturation values for each participant.

The results revealed a clear and unexpected divergence in thresholds. Hemoglobin mass rose significantly only in residents living at 2180 meters or higher, with the effect becoming firmly established at 2600 meters. Plasma volume, by contrast, was already significantly reduced at 1730 meters—roughly 450 meters lower than the erythropoietic threshold. Between the lowest and highest study locations, hemoglobin concentration increased by about 1.0 grams per deciliter in men and 1.3 grams per deciliter in women, while hematocrit rose by roughly 3.2 to 3.7 percentage points. Relative to lean body mass, hemoglobin mass was 5.8 percent higher in men and 8.9 percent higher in women at 2600 meters compared with 970 meters, while plasma volume per kilogram of lean mass fell by about 6 percent in both sexes.

The physiological logic behind these two thresholds traces back to the shape of the oxygen dissociation curve. This sigmoid curve allows arterial blood to remain nearly fully saturated with oxygen up to altitudes of roughly 2000 meters, meaning the kidneys—the primary sensors of oxygen availability—detect little reason to stimulate red cell production. Below that ceiling, the flat upper portion of the curve buffers the modest drop in ambient oxygen pressure. Once saturation begins to fall more steeply, however, the kidney responds by releasing erythropoietin, triggering the bone marrow to expand hemoglobin mass. Plasma volume regulation operates on a different logic entirely: it responds to the overall oxygen-carrying deficit rather than to a specific saturation threshold, and it does so within days rather than weeks.

When the researchers combined their data with earlier measurements taken at 420 and 3800 meters in Bolivia using the same methodology, a striking pattern emerged. Hemoglobin mass increased slowly and modestly up to about 2600 meters, then climbed sharply at higher elevations, reaching values 27 percent above near-sea-level levels at 3800 meters. Notably, within the moderate-altitude range of the current study, there was no significant relationship between hemoglobin mass and oxygen saturation—suggesting that up to roughly 2600 meters, altitude exerts only a gentle influence on erythropoiesis. Above that point, the diminishing oxygen supply becomes the dominant driver, most likely registered by oxygen-sensing mechanisms in the kidneys.

To quantify how much each component contributed to the observed rise in hemoglobin concentration, the team performed multiple regression analyses. The calculations showed that every 100-gram increase in hemoglobin mass raised concentration by 1.59 grams per deciliter, while every liter of plasma volume loss raised it by 3.07 grams per deciliter. Applying these coefficients to the altitude-related changes, the researchers found that of the 1.2 grams per deciliter elevation in hemoglobin concentration at 2600 meters, approximately 0.56 grams per deciliter was attributable to increased hemoglobin mass and 0.61 grams per deciliter to reduced plasma volume—a near-perfect split. When the team applied an alternative correction for the Fåhraeus effect, which accounts for differences between central and peripheral hematocrit, the plasma volume contribution grew even larger.

The findings carry immediate clinical weight. Hemoglobin concentration is one of the most commonly ordered diagnostic measurements in medicine, and anemia thresholds are already adjusted for altitude. Yet the hemoconcentration caused by plasma volume contraction at moderate elevations has never been factored into those thresholds. If a substantial fraction of the altitude-related rise in hemoglobin reflects a shrunken liquid blood volume rather than genuinely enhanced oxygen-carrying capacity, then current anemia criteria may misclassify residents of towns like Bogotá at 2600 meters. The study also resonates with recent work on high-altitude populations worldwide: data from Sherpa communities in the Himalayas suggest their lower hemoglobin concentrations compared with Andean highlanders stem largely from larger plasma volumes rather than smaller hemoglobin masses, underscoring that the ratio of red cells to plasma, not red cell count alone, defines the blood’s oxygen transport profile.

The authors acknowledge limitations. Sample sizes at individual altitudes were modest, and the high interindividual variability in hemoglobin mass—driven largely by differences in lean body mass—means the altitude effect, though statistically robust, is just one of several factors shaping any person’s blood profile. Ambient temperature may also play a role, since the lowland study sites were considerably warmer, and heat acclimatization is known to expand plasma volume. Plasma volume itself was calculated indirectly rather than measured directly, and the Fåhraeus correction introduces some uncertainty, though the researchers showed that an altitude-adjusted correction strengthened rather than weakened their conclusions. Nevertheless, the study provides the first systematic evidence that the blood’s response to moderate altitude unfolds in two distinct stages: plasma contracts first, at around 1730 meters, and the erythropoietic machinery follows at roughly 2180 meters. For the roughly 5 percent of humanity living above 1500 meters, that distinction may soon matter at the doctor’s office as much as on the mountain.

Subject of Research: Altitude thresholds for hemoglobin mass and plasma volume regulation and their effects on hemoglobin concentration in Andean residents

Article Title: Altitude thresholds for hemoglobin and plasma volume regulation in adult residents of different altitudes and their impact on hemoglobin concentration

Article References: Cristancho‐Mejía, E., Trompetero‐Gonzalez, A. C., Benavides‐Pinzón, W. F., & Schmidt, W. F.-J. (2026). Altitude thresholds for hemoglobin and plasma volume regulation in adult residents of different altitudes and their impact on hemoglobin concentration. Physiological Reports, 14(19), Article e71108. https://doi.org/10.14814/phy2.71108

Image Credits: AI Generated

DOI: 10.14814/phy2.71108

Keywords: hemoglobin mass, plasma volume, altitude, hypoxia, erythropoiesis, Andes, Colombia, anemia thresholds, oxygen saturation, blood volume, CO rebreathing, physiology

The study, led by Nadja Deflorin and Tsogyal Daniela Latshang of the Cantonal Hospital of Grisons in Chur, Switzerland, enrolled 44 healthy adults, half of them women, with a median age of 47 years. All participants lived above 1000 meters, at a median home altitude of 1230 meters, and none had spent a night below 1000 meters in the four weeks before testing. Each volunteer underwent polysomnography for two consecutive nights at home and, after a two-week washout period, two consecutive nights at the sleep laboratory in Chur at 590 meters. The order of testing was randomized with a computer-generated sequence, and the trial was registered at clinicaltrials.gov under identifier NCT05826808. Of 176 planned recordings, 174 were completed successfully, a remarkably high data completion rate for portable sleep studies.

The primary outcome was T90, the amount of time spent during sleep with blood oxygen saturation below 90 percent, a measure that previous research has linked to cardiovascular mortality. At home altitude, participants spent an average of 5 minutes per night below this threshold, compared with just 1 minute at 590 meters, a mean difference of 4 minutes that reached statistical significance. Nocturnal oxygen saturation rose from an average of 93.8 percent at moderate altitude to 95.2 percent at low altitude. More striking were the breathing metrics: the apnea-hypopnea index, which counts the number of breathing interruptions per hour, fell from 14.2 events per hour at home to 9.2 events per hour at 590 meters, while the oxygen desaturation index dropped from 10.0 to 6.0 events per hour.

The reduction in overall apnea-hypopnea index was driven almost entirely by obstructive events rather than central ones. Obstructive apneas and hypopneas, in which the upper airway collapses or narrows despite continuing respiratory effort, fell from 13.4 to 8.6 events per hour at the lower altitude, while central events showed no significant change. This pattern aligns with earlier observations that long-term high-altitude residents are prone to obstructive rather than periodic central breathing disturbances, because their physiological adaptations to chronic hypoxia, including larger lung volumes and greater tolerance of low oxygen, prolong the time it takes for falling saturation to trigger an arousal. The authors also point to anatomical factors, noting that highland populations often show larger neck circumferences and higher waist-hip ratios, potentially related to diets rich in salt, meat, and fat, all of which favor airway collapse during sleep.

Sleep architecture itself shifted only modestly with descent. Slow wave sleep, the deep restorative stage, was significantly higher on the second night at 590 meters, reaching 10 percent of total sleep time compared with 8 percent at home altitude, likely because fewer breathing disturbances meant fewer micro-arousals fragmenting the night. Transcutaneous carbon dioxide levels were slightly higher at low altitude during the first night, particularly during non-REM sleep, reflecting the reduced ventilatory drive that comes with richer inspired oxygen. Morning systolic blood pressure was also lower at 590 meters, averaging 115 millimeters of mercury compared with 120 at home, though values remained within the normal range. Questionnaires told a different story: participants rated their subjective sleep quality, sleepiness, and insomnia symptoms identically at both altitudes, unaware that their bodies were behaving differently.

One of the most clinically consequential findings concerned disease classification. At home altitude, six of the 44 participants, or 13.6 percent, crossed the threshold for severe obstructive sleep apnea with an apnea-hypopnea index above 30 events per hour. At 590 meters, only one participant, or 2.3 percent, met that criterion, a statistically significant difference. In other words, a diagnostic study performed at a lower-altitude laboratory would have labeled five people as not having severe sleep apnea who, sleeping in their own beds, clearly did. The authors conclude that sleep-disordered breathing assessments conducted at lower-than-living altitude may systematically underestimate the severity of the condition in patients who permanently reside at moderate elevation.

The trial also uncovered a pronounced sex difference. In male participants, descent to low altitude produced a larger effect on T90, with a mean difference of 7 minutes, and on REM sleep, which increased by 4 percent of total sleep time at the lower elevation. Regression analyses identified male sex as a significant predictor of both T90 and the oxygen desaturation index, with age also predicting desaturation frequency. Among males, 27.3 percent showed severe sleep apnea at home altitude versus essentially none at 590 meters, while no females crossed the severe threshold at either altitude. The researchers suggest that women may regulate breathing better at moderate altitude, consistent with prior studies at 3270 and 3800 meters showing sex-specific differences in hypoxic ventilatory response, loop gain, upper airway anatomy, and carbon dioxide reserve.

The physiological logic behind these results rests on the interplay between inspired oxygen pressure and ventilatory control. At 1230 meters, the partial pressure of inspired oxygen is low enough to destabilize breathing during sleep, particularly in REM stages when the ventilatory response to both hypoxia and hypercapnia naturally wanes and respiratory effort after airway occlusion diminishes. Descending to 590 meters raises inspired oxygen pressure, stabilizes the control system, and shortens the duration of each obstructive event because arterial saturation falls below arousal-triggering thresholds more quickly. The effect appeared within a single night, indicating that even brief exposure to lower altitude is sufficient to alter the diagnostic picture, and the two-week washout at home altitude confirmed the changes were reversible and altitude-dependent.

The authors recommend that polysomnography for patients living above 1000 meters be performed at their individual home elevations whenever possible, especially for male patients in whom the altitude effect on oxygenation, REM sleep, and apnea severity was most pronounced. They caution that their findings come from healthy volunteers and may not extend directly to patients with severe comorbidities or to those living at substantially higher elevations, and they call for further studies in people with diagnosed obstructive sleep apnea and for deeper investigation of sex differences. Still, the message for the millions of highlanders worldwide is clear: where you sleep when the sensors are attached matters, and a valley-floor clinic may paint a deceptively rosy picture of what happens in a mountain bedroom.

Subject of Research: The effect of short-term descent to low altitude on sleep-disordered breathing in healthy moderate-altitude residents

Article Title: The effect of short-term descent to low altitude in healthy residents at moderate altitude — a randomized crossover trial

Article References: Deflorin, N., Furian, M., Vontobel, J., Niederseer, D., & Latshang, T. D. (2026). The effect of short-term descent to low altitude in healthy residents at moderate altitude — a randomized crossover trial. Journal of Clinical Sleep Medicine, 22(1), Article 122. https://doi.org/10.1007/s44470-026-00128-1

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00128-1

Keywords: sleep apnea, polysomnography, altitude, hypoxemia, sleep-disordered breathing, apnea-hypopnea index, oxygen saturation, REM sleep, slow wave sleep, randomized crossover trial, high-altitude residents, sex differences

The scale of the issue is easy to underestimate. Recent global estimates of human population distribution suggest that a substantial share of humanity lives at moderate or high elevation, with large concentrations in the Andes, the Himalayan plateau and its surroundings, the highlands of East Africa, and the mountainous interior of Mexico and Central America. Cities such as Bogotá, Mexico City, Quito, La Paz, Kathmandu, and Denver all sit at altitudes where barometric pressure, and therefore the partial pressure of inspired oxygen, is significantly reduced compared with conditions at sea level. For the residents of these cities, sleep does not occur in the same physiological environment that most sleep medicine textbooks implicitly assume, and that mismatch has consequences for how breathing during sleep is measured, scored, and interpreted.

The core physics are straightforward but their downstream effects are not. As altitude increases, barometric pressure falls, and with it the partial pressure of oxygen in inspired air. The body responds with a suite of acclimatization mechanisms: ventilation rises, producing a mild respiratory alkalosis as carbon dioxide is washed out; oxygen saturation of hemoglobin drifts downward, particularly during sleep; and the chemoreflexes that govern breathing become more sensitive to changes in carbon dioxide and oxygen. During wakefulness these adjustments are usually well tolerated. During sleep, however, the normal withdrawal of the behavioral and cortical drive to breathe leaves chemical control in charge, and at altitude that chemical control system becomes unstable. The result is a characteristic pattern of periodic breathing, in which ventilation waxes and wanes in regular cycles, sometimes culminating in central apneas, pauses in breathing that originate not in blocked airways but in an over-responsive control loop.

This instability is often described in terms of loop gain, a control-systems measure of how strongly the respiratory system amplifies a small perturbation in blood gases. At altitude, the reduced inspired oxygen raises the gain of the peripheral chemoreflex, so a modest dip in oxygen saturation triggers a larger ventilatory response than it would at sea level. The resulting over-ventilation lowers carbon dioxide below the threshold needed to keep breathing going, breathing pauses follow, and the cycle repeats. Sleep itself amplifies the problem, because the carbon dioxide threshold for maintaining breathing rises during non-REM sleep, narrowing the window between apneic and hyperpneic thresholds. Classic laboratory work has shown that hypocapnic apneas and hypopneas develop readily during NREM sleep under hypoxic conditions, and more recent field studies have documented that these loop-gain effects differ between men and women, with sex-related differences in the propensity for high-altitude sleep-disordered breathing.

The clinical consequence is that a sleep study performed at 2,600 meters may look different from the same study performed at sea level, in the same person, on the same equipment. Oxygen saturation values that would be flagged as abnormal at low altitude may be unremarkable for a healthy resident of a high-altitude city, and thresholds used to score hypopneas or to calibrate oxygen therapy may need local adjustment. Studies of healthy adults sleeping at around 2,240 meters, for example, have documented breathing patterns and saturation levels that depart from low-altitude norms without indicating disease, while work in Bogotá at 2,640 meters has examined how apnea severity and oxygenation measures shift in adults living at that elevation. Conversely, patients with obstructive sleep apnea who live at altitude may show a distinct phenotype: research on high-altitude populations has described a predominance of REM-related obstructive events, a pattern with implications for how severity is graded and how treatment is titrated.

Altitude does not only add central events to the picture; it can also unmask or aggravate obstructive disease. The intermittent desaturation that accompanies upper airway narrowing is amplified when the baseline saturation is already lower, so the same degree of airway collapse produces deeper and longer oxygen dips at elevation. Some investigators have argued that mild chronic high-altitude exposure contributes to the comorbidity burden of obstructive sleep apnea-hypopnea syndrome, potentially worsening cardiovascular and metabolic risk. Comparative data from sleep clinics at different elevations in the mountain west of the United States have shown that altitude-associated central apnea can complicate both the diagnosis and the treatment of obstructive sleep apnea, because positive airway pressure therapy that works well at one elevation may behave differently at another, and residual central events may appear or disappear as patients move between altitudes.

That last point, the effect of moving between elevations, is where the newest evidence becomes particularly striking. A randomized crossover trial published in the same journal examined healthy residents of a moderate-altitude city who descended to low altitude for short periods, and found that even brief descent changed their sleep and breathing physiology. Meanwhile, an earlier study of patients with obstructive sleep apnea who traveled from moderate elevation to sea level documented changes in apnea severity with descent, and clinical experience in mountain regions has long noted that patients referred for sleep testing shortly after travel to a different altitude may yield results that do not reflect their usual condition. In practical terms, a sleep study is a snapshot not only of a patient but of the atmospheric conditions under which it was recorded, and the commentary argues that this context belongs in the interpretation.

What would it mean to take altitude seriously in sleep medicine? The commentary points toward several concrete adjustments. Reference values for oxygen saturation, desaturation indices, and normal breathing patterns during sleep should ideally be established or calibrated for the elevation at which testing occurs, rather than imported wholesale from low-altitude populations. Scoring conventions and severity thresholds might need altitude-specific interpretation, so that a given apnea-hypopnea index or saturation nadir is read in light of the local barometric environment. Clinicians should routinely record the altitude of the sleep laboratory or home testing device and consider it when reporting results, and should ask patients about recent travel between elevations before drawing conclusions from a single night. Researchers designing trials of sleep-disordered breathing, and reviewers comparing studies from different centers, face a parallel obligation: a multicenter study that pools data from Quito and Amsterdam without accounting for a 2,800-meter difference in testing conditions may be averaging away a real biological signal.

There is also a broader equity dimension that the commentary raises implicitly through its own vantage point. Sleep medicine guidelines, reference datasets, and device algorithms have historically been developed and validated largely at low altitude, in North American, European, and East Asian lowland populations. Yet a meaningful fraction of the world’s population lives at elevations where those assumptions are strained, and many of the countries most affected, including Colombia, Bolivia, Peru, Ecuador, Mexico, Nepal, and Ethiopia, have limited access to the specialized sleep centers where local normative data could be generated. Building altitude-aware sleep medicine is therefore not only a matter of physiological precision but of making diagnostics valid for the populations that actually use them. The author, who declares no competing interests and reports no specific funding for the commentary, frames the question as one that the field can no longer defer.

The takeaway for readers is deceptively simple: altitude matters, and it matters in both directions. For the lowlander who travels to the mountains, a few nights of periodic breathing and fragmented sleep are usually a normal acclimatization response, not a new disease, though they can complicate any testing done during the stay. For the high-altitude resident, the thinner air is home, and the sleep study that ignores it risks mislabeling normal physiology as pathology or, more dangerously, underestimating disease that is amplified by hypoxic stress. As home sleep apnea testing spreads to ever more diverse environments, the elevation printed on the report may deserve the same attention as the patient’s age, sex, and body mass index. The commentary’s message to the sleep medicine community is that the atmosphere is not background noise in a sleep study; it is part of the experiment.

Subject of Research: The influence of altitude on sleep-disordered breathing physiology and the interpretation of sleep studies

Article Title: Sleep studies: does the altitude matter?

Article References: Bazurto-Zapata, M. A. (2026). Sleep studies: does the altitude matter?. Journal of Clinical Sleep Medicine, 22(1), Article 142. https://doi.org/10.1007/s44470-026-00151-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00151-2

Keywords: sleep medicine, altitude, hypoxia, polysomnography, obstructive sleep apnea, central apnea, periodic breathing, loop gain, oxygen saturation, high-altitude populations, respiratory physiology, REM sleep

Acute mountain sickness is far more than an inconvenience. Headache, dizziness, nausea, vomiting, and fatigue can degrade judgment and performance, and in severe cases the condition can progress to high-altitude cerebral edema or high-altitude pulmonary edema, both of which are life threatening. As modern transportation makes it possible to fly from Beijing to the Tibetan plateau in under five hours, the number of people exposed to sudden, severe hypoxia has risen sharply. Yet the tools available to predict who will fall ill remain frustratingly limited, often requiring hypoxic gas generators, hypobaric chambers, blood biomarkers, or expensive imaging equipment that is unrealistic for field deployment.

The research team, drawn from Tsinghua University and collaborating institutions, recruited 48 healthy low-altitude residents aged 18 to 31 years with no high-altitude exposure in the preceding year. After strict screening for cardiovascular disease, chronic respiratory conditions, hypertension, and medications affecting cardiopulmonary function, 44 participants completed the full protocol. At 50 meters above sea level, each volunteer performed a standardized step test involving three minutes of seated rest, five minutes of stepping at 22.5 steps per minute on a platform 35 centimeters high for women and 40 centimeters for men, and four minutes of seated recovery. Throughout the protocol, a finger-clip pulse oximeter continuously recorded heart rate and peripheral oxygen saturation, while investigators monitored pulse waveforms to discard any artifactual readings.

Days later, the same participants boarded a commercial flight from Beijing to Lhasa, followed by a bus transfer to an experimental base, with all arrivals synchronized between 14:00 and 15:00 to minimize travel-fatigue confounds. The following morning, 18 hours after arrival, researchers administered the Lake Louise Score, the widely used self-report instrument for AMS, under blinded conditions in an independent space. Nineteen of the 44 participants met the diagnostic criteria for AMS, defined as a score of 3 or greater with headache plus at least one additional symptom.

Back at low altitude, the physiological data told a clear story. Variables captured during exercise and recovery, including estimated maximal oxygen uptake, exercise oxygen saturation, recovery oxygen saturation, exercise heart rate, recovery heart rate, and a composite step index, were all significantly correlated with subsequent AMS severity. In contrast, resting heart rate and resting oxygen saturation showed no meaningful association. This distinction matters physiologically: a resting baseline rarely exposes hidden limitations in ventilatory or cardiovascular compensation, whereas the added oxygen demand of exercise can reveal subtle deficits in how efficiently the body shuttles and utilizes oxygen, mimicking in miniature the stress that sudden altitude exposure imposes.

To translate these observations into a classification framework, the researchers applied k-means clustering, an unsupervised machine learning algorithm that groups individuals based on similarity of features without requiring predefined labels. After standardizing the data and reducing dimensionality with principal component analysis, the team tested multiple combinations of physiological variables. The strongest and most accurate stratification emerged from four indicators: estimated VO2max, exercise oxygen saturation, recovery oxygen saturation, and the step index. This combination yielded a silhouette coefficient of 0.767, indicating a strong two-cluster structure, and achieved a within-cohort accuracy of 93.18 percent when evaluated against the actual Lake Louise classifications.

Perhaps most striking was the sensitivity of the approach. All 19 participants who developed AMS were assigned to the AMS-susceptible cluster, and none of the 22 participants in the non-susceptible cluster developed symptoms. The authors are careful to note that these figures represent within-cohort clustering performance rather than validated predictive accuracy in an independent sample, and that no false-negative assignments in a new cohort cannot be guaranteed. Nevertheless, the effect sizes separating the two clusters were substantial, with Cohen’s d values ranging from 0.99 for estimated VO2max to 1.75 for the step index, and the Lake Louise Score itself differed markedly between clusters.

The team went to considerable lengths to confirm the clustering was not an artifact. Bootstrap resampling across 3000 replicates produced a median Jaccard stability index of 0.803, well within the range considered stable. Alternative algorithms including fuzzy c-means, partitioning around medoids, Gaussian mixture models, spectral clustering, and Ward hierarchical clustering broadly reproduced the same partition. When estimated VO2max was deliberately perturbed with realistic measurement error, or excluded entirely, the core structure persisted with only modest degradation. Sex, which some prior studies have linked to AMS susceptibility, showed no significant association with cluster membership, and statistically removing sex-related differences in estimated fitness left every participant in their original cluster.

The most influential single variable turned out to be the step index, a simple composite derived from recovery heart rates and exercise duration. Though modest alone, it combined powerfully with exercise oxygenation measures to separate the two physiological phenotypes. The authors suggest this reflects the fundamental importance of cardiorespiratory reserve: people whose bodies recover quickly from submaximal exertion and who maintain oxygen saturation under load appear better equipped to handle the abrupt hypoxic burden of rapid ascent. Three participants classified as susceptible but who scored below the AMS threshold may represent individuals with genuinely compromised reserves or, alternatively, conservative symptom self-reporting that underestimated their true Lake Louise Scores.

The implications for public health and occupational medicine are considerable. Mountaineers, military personnel, railway and construction workers, pilgrims, and ordinary tourists all stand to benefit from a screening method that requires nothing more than a step platform, a pulse oximeter, and twelve minutes of time. Unlike hypoxic chamber tests or blood-based omics panels, the protocol is easily standardized and could plausibly be administered at worksites, travel clinics, or recruitment centers. The authors emphasize that the approach remains exploratory and requires validation in larger, more diverse cohorts spanning different ages, health statuses, ascent profiles, and altitude targets, and that severe outcomes such as high-altitude cerebral or pulmonary edema were not represented in this young, healthy sample. Still, the study demonstrates that meaningful physiological structure emerges from a test simple enough to be administered almost anywhere, offering a glimpse of a future in which altitude illness risk can be identified and mitigated before the first symptom ever appears.

Subject of Research: Prediction of acute mountain sickness susceptibility using low-altitude step test data and unsupervised machine learning clustering

Article Title: Clustering analysis of acute mountain sickness susceptibility among young adults during rapid ascent using low‐altitude step test data

Article References: Wei, S., Ji, L., Liu, K., & Lu, Y. (2026). Clustering analysis of acute mountain sickness susceptibility among young adults during rapid ascent using low‐altitude step test data. Physiological Reports, 14(17), Article e71091. https://doi.org/10.14814/phy2.71091

Image Credits: AI Generated

DOI: 10.14814/phy2.71091

Keywords: acute mountain sickness, step test, k-means clustering, hypoxia, high altitude, machine learning, oxygen saturation, cardiorespiratory fitness, Lake Louise Score, rapid ascent, pulse oximetry, physiological screening